FDA clears return of GSK’s once-withdrawn multiple myeloma drug

GSK's multiple myeloma drug Blenrep has received a partial FDA approval, marking its return to the U.S. market after being pulled in 2022 due to prior trial failures and toxicity concerns. The approval allows Blenrep's use in combination with Velcade for patients who have undergone at least two prior lines of therapy, based on the DREAMM-7 study which demonstrated significant improvements in progression-free survival and reduced mortality risk. While the drug faces intense competition from newer BCMA-targeting cell therapies and bispecifics, and requires careful management of eye toxicity, this clearance represents a strategic win for GSK, particularly given Blenrep's potential for broader administration across various healthcare settings.

Analysis

GSK's multiple myeloma drug, Blenrep, has secured a partial FDA re-approval for the U.S. market, marking a significant turnaround after its withdrawal in 2022. The approval permits its use in combination with Velcade for patients who have undergone at least two prior lines of therapy, a more restrictive indication than GSK initially sought. This decision, based on the DREAMM-7 study, demonstrated a halving of death risk and a tripling of median progression-free survival for the Blenrep-Velcade regimen. GSK's Chief Scientific Officer Tony Wood referred to the decision as a "significant milestone."

The re-approval follows Blenrep's initial market exit due to a failed confirmatory trial and concerns over ocular toxicity, despite being the first BCMA-targeting drug. Despite a prior negative FDA advisory panel vote in July and concerns outlined in briefing documents, the agency cleared the drug, acknowledging the urgent need for novel therapies in relapsed/refractory multiple myeloma. This partial clearance underscores the drug's renewed clinical efficacy in specific regimens.

While Blenrep faces heightened competition from established cell therapies and bispecific drugs now used earlier in treatment, improved physician experience in managing its eye toxicity through dose adjustments and eye drops could aid adoption. Furthermore, its unique ability to be administered "across healthcare settings," including community centers, provides a potential competitive advantage for market penetration, particularly given the strong positive sentiment (0.75) surrounding this development for GSK.

Key Decisions for Investors

• Investors should assess the revenue potential of Blenrep's re-approval, considering the partial indication and competitive landscape against its unique administration advantage in community settings.
• Monitor GSK's market penetration strategy and sales figures for Blenrep, particularly observing its uptake and the impact of improved toxicity management on physician prescribing patterns.
• Evaluate the broader implications for GSK's oncology pipeline and R&D strategy, as this re-approval validates their persistence with a previously challenged asset and could signal future development approaches.